戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 sed patients (71%) with cytogenetic data had trisomy 8.
2 g increased Fas susceptibility of cells with trisomy 8.
3 osomal aberrations were trisomy 22 (18%) and trisomy 8 (16%).
4 M5 morphology, and frequently had additional trisomy 8 (39.6%; P < .001).
5 ing abnormalities included trisomy 15 (49%), trisomy 8 (46%), and -X/-Y (54%).
6  constitutes the single largest group, while trisomy 8 (+8) as a sole abnormality is the most frequen
7 55, 11.5%), inv(16)/t(16;16) (n = 28, 5.9%), trisomy 8 alone (n = 10, 2.1%), monosomy 7 (n = 9, 1.9%)
8                     The prognostic impact of trisomy 8, alone or with other clonal aberrations, was e
9  cohort, TERT mutations were associated with trisomy 8 and inversion 16.
10 es maintained the ring chromosome 4, but the trisomy 8 and trisomy 18 segregated into BLIN-4E and BLI
11                Our findings demonstrate that trisomy 8 and trisomy 20 are also nonrandom aberrations
12                                              Trisomy 8 and trisomy 20 are nonrandom aberrations in de
13                                              Trisomy 8 and trisomy 20 were detected by molecular cyto
14 normalities associated with MDS (monosomy 7, trisomy 8, and 5q-) for evidence of apoptosis.
15 es often occur in the setting of monosomy 7, trisomy 8, and acquired mutations in ASXL1 or in STAG2.
16 ar abnormalities, such as t(11q23), isolated trisomy 8, and FLT3-ITD mutations.
17 sociated with HSTCL are isochromosome 7q and trisomy 8, and most cases harbor mutations in genes invo
18 ment of APL differs in each group: FLT3-ITD, trisomy 8, and other genomic changes.
19                                   Cells with trisomy 8 appear to be more susceptible to Fas-mediated
20 percent of patients who had de novo MDS with trisomy 8 as the sole karyotypic abnormality responded t
21 e, with stable increase in the proportion of trisomy 8 bone marrow cells and normalization of the T-c
22 ng CD34 cells was increased in patients with trisomy 8, but decreased in monosomy 7, as compared with
23 YC protooncogene is of central importance in trisomy 8, but the experimental data to support this are
24  low levels of DNA degradation in annexin(+) trisomy 8 CD34 cells, which were comparable with annexin
25 ed comparable colony formation by annexin(+) trisomy 8(-) CD34(+) and annexin(-) CD34 cells.
26  not of the remaining subfamilies, inhibited trisomy 8 cell growth in short-term hematopoietic cultur
27          Fas expression was increased in the trisomy 8 cells and decreased in the monosomy 7 cells wh
28 ber of T cells with apparent specificity for trisomy 8 cells is consistent with an autoimmune pathoph
29             Conversely, deleting one copy in trisomy 8 cells largely neutralizes the fitness benefit
30                   These results suggest that trisomy 8 cells undergo incomplete apoptosis and are non
31                                              Trisomy 8 cells were more likely to express activated ca
32                                              Trisomy 8 cells were resistant to apoptosis induced by g
33 in by siRNA resulted in preferential loss of trisomy 8 cells.
34                               Paradoxically, trisomy 8 clones can persist in patients with bone marro
35 bclones, as demonstrated by the results from trisomy 8 clones of the myelodysplastic syndromes (MDS)
36                                 In contrast, trisomy 8 developed in patients with good hematologic re
37 e genomic abnormalities: 8 samples (17%) had trisomy 8 either with or without an additional duplicati
38                                    Thus, the trisomy 8 group as a whole had poor survival, which was
39                 Patients with monosomy 7 and trisomy 8 have distinctly different clinical courses, re
40 , we found that human myeloid leukemias with trisomy 8 have increased MYC.
41 ilms tumor 1 (WT1) gene was overexpressed by trisomy 8 hematopoietic progenitor (CD34(+)) cells compa
42  P = .006), trisomy 22 (HR = 0.45; P = .07), trisomy 8 (HR = 2.26; P = .02), age (difference of 10 ye
43 llular marrow and, unexpectedly, evidence of trisomy 8 in 21.6% of cells.
44 0%); the most common were -Y in 25 (43%) and trisomy 8 in 7 patients (12%).
45 similar prognosis to those with primary MDS, trisomy 8 in AA appears to have a more favorable prognos
46                  We studied 34 patients with trisomy 8 in bone marrow cells, some of whom were underg
47    Traditional cytogenetic analysis revealed trisomy 8 in two cases of osteofibrous dysplasia.
48                                              Trisomy 8 is a frequent cytogenetic abnormality in bone
49        Aneuploidy, especially monosomy 7 and trisomy 8, is a frequent cytogenetic abnormality in the
50 erations, including the murine equivalent of trisomy 8, loss of the AML commonly deleted region on ch
51 inct molecular mechanisms for monosomy 7 and trisomy 8 MDS and implicate specific pathogenic pathways
52                   Previously, we showed that trisomy 8 MDS patients had clonally expanded CD8(+) T-ce
53 istent with an autoimmune pathophysiology in trisomy 8 MDS.
54 gulated in CD34 cells of both monosomy 7 and trisomy 8 MDS.
55 isomy 8 relative to healthy controls and non-trisomy 8 MDS; WT1 protein levels were also significantl
56    Using an evolution approach, we show that trisomy 8 mitigates EWS-FLI1-induced replication stress
57                                              Trisomy 8 mosaicism (T8M) was subsequently diagnosed by
58                CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) are distinguish
59 by way of complex karyotype (n = 41) or sole trisomy 8 (n = 21).
60 duplication of the BCR-ABL1 gene (n = 8) and trisomy 8 (n = 3), recurrent submicroscopic alterations,
61  14q11 breakpoints, 15 with del(9p), 11 with trisomy 8, nine with 11q23 breakpoints, nine with 14q32
62 nist facilitated the expansion of cells with trisomy 8 only.
63                                    Moreover, trisomy 8 or amplification of 8q24 (MYC) was almost excl
64                     Interphase BM cells with trisomy 8 or monosomy 7 increased in 6 of 6 patients wit
65                                              Trisomy 8 or monosomy 7 was shown by fluorescence in sit
66 a low percentage of cells also having either trisomy 8 or trisomy 18.
67 ples (23%) had genomic abnormalities without trisomy 8 (other abnormalities group).
68 arrow mononuclear cells of MDS patients with trisomy 8 relative to healthy controls and non-trisomy 8
69 mplex karyotype without monosomies, and sole trisomy 8, respectively (P < .0001).
70 7 accounted for 40% of all cases followed by trisomy 8, structural and numerical abnormalities of chr
71 ing the responsiveness of some patients with trisomy 8 to anti-thymocyte globulin (ATG) and cyclospor
72                                           In trisomy 8, up-regulated genes were primarily involved in
73 tained from MDS patients with monosomy 7 and trisomy 8 using Affymetrix GeneChips.
74 le to worsened outcomes among patients whose trisomy 8 was associated with other unfavorable cytogene
75 Fas antagonist, the percentage of cells with trisomy 8 was significantly decreased in most cases afte
76 1 with a relatively good prognosis including trisomy 8, -Y, and an extra copy of Philadelphia chromos